20 results about "Schizophrenic disorders" patented technology

This disclosure relates to dosage forms comprising bupropion hydrochloride, another salt form of bupropion, or the free base form of bupropion; dextromethorphan hydrobromide, another salt form of dextromethorphan, or the free base form of dextromethorphan, and a polymer. In some embodiments, the dosage form has no significant dose dumping of bupropion in the presence of ethanol in vitro. In some embodiments, the dosage form does not have a food effect for bupropion or dextromethorphan when taken with a high-fat meal in human subjects. Some embodiments include a method of treating a nervous system condition (such as depression, e.g., major depressive disorder, including treatment-resistant depression, agitation associated with Alzheimer's disease (or agitation associated with dementia of the Alzheimer's type), agitation associated with dementia, anxiety (or generalized anxiety disorder), neuropathic pain, or peripheral diabetic neuropathic pain) comprising, administering a dosage form described herein to a human being in need thereof.

This disclosure relates to dosage forms comprising bupropion hydrochloride, another salt form of bupropion, or the free base form of bupropion; dextromethorphan hydrobromide, another salt form of dextromethorphan, or the free base form of dextromethorphan, and a polymer. In some embodiments, the dosage form has no significant dose dumping of bupropion in the presence of ethanol in vitro. In some embodiments, the dosage form does not have a food effect for bupropion or dextromethorphan when taken with a high-fat meal in human subjects. Some embodiments include a method of treating a nervous system condition (such as depression, e.g., major depressive disorder, including treatment-resistant depression, agitation associated with Alzheimer's disease (or agitation associated with dementia of the Alzheimer's type), agitation associated with dementia, anxiety (or generalized anxiety disorder), neuropathic pain, or peripheral diabetic neuropathic pain) comprising, administering a dosage form described herein to a human being in need thereof.

Compositions for intranasal delivery of olanzapine and methods for their use to treat various symptoms of schizophrenia, schizoaffective disorder, and bipolar I disorder, such as acute agitation, mania, and mixed episodes. Intranasal olanzapine compositions comprise dodecyl maltoside to improve bioavailability of olanzapine and is administered via nasal mucosa to avoid direct systemic administration.

The invention provides an oral soluble film containing cariprazine or pharmaceutically acceptable salts thereof and a preparation method of the oral soluble film. The prepared oral soluble film has excellent effects of taste masking, stability, dissolution and the like, is convenient to take, can effectively improve the compliance of schizophrenia patients, and avoids behaviors of medicine hiding, medicine vomiting and the like.

The present application relates to the field of medical informatics, and provide a paliperidone efficacy prediction method and system based on plasma proteomics, the method comprises the following steps: collecting the basic data of the target patient; selecting the protein features through the basic data to obtain the related proteins corresponding to the paliperidone efficacy; training the neural network based on the related proteins and the baseline data in the basic data to obtain the prediction model; predicting the paliperidone efficacy of the patient to be predicted through the prediction model to obtain the prediction result. The present application can predict the treatment response of schizophrenic patients to paliperidone, and significantly improve the objectivity of paliperidone use.

Compositions for intranasal delivery of olanzapine and methods for their use to treat various symptoms of schizophrenia, schizoaffective disorder, and bipolar disorder, such as acute agitation, mania, and mixed episodes. Intranasal olanzapine compositions comprise dodecyl maltoside to improve bioavailability of olanzapine and is administered via nasal mucosa to avoid direct systemic administration.

The present specification disclose a combined therapy comprising one or more activators of an alpha-7 nicotinic acetylcholine receptor activity having 5-HT3 receptor inhibitory activity and one or more activators of 5-HT3 receptor activity for use in treating a schizophrenic disorder as well as methods of treating a schizophrenic disorder by administering a combined therapy comprising one or more activators of an alpha-7 nicotinic acetylcholine receptor activity having 5-HT3 receptor inhibitory activity and one or more activators of 5-HT3 receptor activity.

Systems and methods for assessing schizophrenia, for example severity of schizophrenia, may use a trained machine learning model. An audio recording of a patient may be processed to determine acoustic data related to the audio recording. The system may determine, for example using the trained machine learning model, a digital biomarker. The digital biomarker may correspond to schizophrenia severity of the patient using the acoustic data. The digital biomarker may correspond to a positive and negative syndrome scale (PANSS) score. For example, the digital biomarker may include an indication of one or more symptoms and / or the severity of schizophrenia.

The disclosure provides the use of particular substituted heterocycle fused gamma-carboline compounds as pharmaceuticals for the treatment of residual symptoms of psychosis or schizophrenia. The disclosure also provides novel long acting injectable formulations of particular substituted heterocycle fused gamma-carboline compounds and use of such long acting injectable formulations for the treatment of residual symptoms of psychosis or schizophrenia.

The present invention relates to a method for differentiating patients across healthy control, bipolar disorder, schizophrenia, and schizoaffective groups. The present invention is drawn to an in vitro method for differential diagnosis of schizophrenia versus schizoaffective versus bipolar disorder in a patient the method comprising the determination in a blood sample of the patient of the relative proportion of at least one of the RNA editing-based biomarkers, IFNAR1, IFNAR2 and AHR, exhibiting A-to-l RNA editing. The present invention also relates to a method for determining the effectiveness of a therapy, or to predict or monitor treatment of such disorder and to a kit to implement the method of the present invention using pairs of primers.

To provide use of valbenazine for treating schizophrenia or schizoaffective disorder.SOLUTION: The present invention provides a method of treating schizophrenia or schizoaffective disorder, by administering (S)-2-amino-3-methyl-butanoic acid(2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido [2,1-a]isoquinoline-2-yl ester, or an isotopic variant thereof, or a pharmaceutically acceptable salt or polymorph thereof to a subject in need thereof.SELECTED DRAWING: None

A compound of formula (I) or a salt thereof are provided:wherein R1, X and R3 are defined in the specification, useful in the treatment of disorders mediated by KMO such as acute pancreatitis, chronic kidney disease, other conditions associated with systemic inflammatory response syndrome (SIRS), Huntington's disease, Alzheimer's disease, spinocerebellar ataxias, Parkinson's disease, AIDS-dementia complex, amylotrophic lateral sclerosis (ALS), depression, schizophrenia, sepsis, cardiovascular shock, severe trauma, acute lung injury, acute respiratory distress syndrome, acute cholecystitis, severe burns, pneumonia, extensive surgical procedures, ischemic bowel, severe acute hepatic disease, severe acute hepatic encephalopathy or acute renal failure.

Deuterated forms of idazoxan according to Formula (I), and their pharmaceutically acceptable salts, pharmaceutical compositions containing these compounds, and methods of treatment or prevention using these compounds or pharmaceutical compositions are described. The compounds are useful for treating or preventing a disease or condition selected from psychosis, schizophrenia, schizoaffective disorder, Parkinson's disease, Lewy body dementia, sleep disorder (including insomnia), agitation, mood disorder (including depression), thromboembolic disorder, autism, and attention deficit hyperactivity disorder.

This invention relates to the treatment of a psychiatric or neurological disorder in a patient in need thereof who has anhedonia (lack of pleasure or motivation to pursue rewarding activities) by administering irdabisant or a pharmaceutically acceptable salt thereof, either as a monotherapy, or in combination with an antipsychotic agent. Examples of such psychiatric or neurological disorder include major depressive disorder, bipolar depression (such as bipolar I or bipolar II disorders), post-traumatic stress disorder, substance use disorder, anhedonia-related aspects of schizophrenia (e.g., negative symptoms) and schizoaffective disorder (e.g., with mood and / or negative symptoms).

The present invention relates to the treatment of psychiatric or neurological disorders in patients in need of pleasant sensation (lack of pleasure or pursuit of incentive activities) by administering idarsone or a pharmaceutically acceptable salt thereof as a monotherapy or in combination with an antipsychotic agent. Examples of such psychiatric or neurological disorders include major depressive disorder, bipolar depression (such as bipolar type I or bipolar type II disorder), post-traumatic stress disorder, substance use disorder, pleasant sensation loss related aspects of schizophrenia (e.g., negative symptoms), and split affective disorder (e.g., with emotional and / or negative symptoms).

Compositions for intranasal delivery of olanzapine and methods for their use to treat various symptoms of schizophrenia, schizoaffective disorder, and bipolar I disorder, such as acute agitation, mania, and mixed episodes. Intranasal olanzapine compositions comprise dodecyl maltoside to improve bioavailability of olanzapine and is administered via nasal mucosa to avoid direct systemic administration.

The invention relates to the treatment of schizophrenia disorders using combination therapy. The present specification discloses a combination therapy comprising one or more activators of alpha-7 nicotinic acetylcholine receptor activity having 5-HT3 receptor inhibitory activity and one or more activators of 5-HT3 receptor activity for use in the treatment of schizophrenia disorders, and methods of treating schizophrenia disorders by administering a combination therapy comprising one or more activators of alpha-7 nicotinic acetylcholine receptor activity and one or more activators of 5-HT3 receptor activity having 5-HT3 receptor inhibitory activity.

The invention relates to a composition comprising a piperazine-benzazepine, a buffer and a surfactant, and uses of such compositions such as treating, preventing, and / or suppressing symptoms of schizophrenia, schizoaffective disorders, and / or Parkinson's disease. The compositions have improved parameters such as a lower variance in pH, improved stability during storage, and lower solubility of piperazine-benzazepines, resulting in piperazine-benzazepine particle formation with improved particle size and particle size distribution. The compositions are useful as therapeutic agent, for instance through parenteral administration to a subject.

Describes deuterated forms of flibanserin of structural formula (I) and pharmaceutically acceptable salts thereof, pharmaceutical compositions containing these compounds, and methods of treatment or prophylaxis using these compounds or pharmaceutical compositions. The compounds can be used for the treatment or prophylaxis of diseases or conditions selected from psychosis, schizophrenia, schizoaffective disorder, Parkinson's disease, dementia with Lewy bodies, sleep disorders (including insomnia), agitation, mood disorders (including depression), thromboembolic disorders, autism and attention deficit hyperactivity disorder. #imgabs0#

本发明提供一种用于促炎细胞因子、成骨转录因子、骨吸收因子以及内源性p62表达调节的新型p62组合物。因而，这样的p62组合物适用于炎症性疾病的预防和治疗，并且本发明还提供了相关方法。在某些实施例中，炎症性疾病与癌症不相关。在一些实施方式中，炎症性疾病包括，但不限于，骨质疏松症、肥胖症、代谢综合征、2型糖尿病、脂肪肝、炎症性肠道疾病、慢性胰腺炎、哮喘、慢性阻塞性肺病（COPD）、类风湿性关节炎（RA）、骨关节炎、多发性硬化症（MS）、银屑病、充血性心力衰竭（CHF）、动脉粥样硬化、神经退行性疾病（ALS，帕金森症、阿尔兹海默症、亨廷顿病）、抑郁症、精神分裂症、痛风、石棉肺以及矽肺。